PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetate.

ABSTRACT:

Background

Loss of the tumor suppressor phosphatase and tensin homolog (PTEN) occurs frequently in prostate cancers. Preclinical evidence suggests that activation of PI3K/AKT signaling through loss of PTEN can result in resistance to hormonal treatment in prostate cancer.

Objective

To explore the antitumor activity of abiraterone acetate (abiraterone) in castration-resistant prostate cancer (CRPC) patients with and without loss of PTEN protein expression.

Design, setting, and participants

We retrospectively identified patients who had received abiraterone and had hormone-sensitive prostate cancer (HSPC) and/or CRPC tissue available for PTEN immunohistochemical analysis.

Outcome measurements and statistical analysis

The primary end point was overall survival fro

SUBMITTER: Ferraldeschi R 

PROVIDER: S-EPMC4410287 | biostudies-literature | 2015 Apr

REPOSITORIES: biostudies-literature